Personalized CRT - PSR

NCT ID: NCT03723265

Last Updated: 2022-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1517 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2022-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the cardiac resynchronization therapy (CRT) response in a real-world patient population and evaluate options to address non-response and patient management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Personalized CRT study is a multi-center, single arm, prospective observational study. The purpose of the study is to better understand and characterize heart failure (HF) patient management by characterizing the use and clinical benefit of Medtronic market-released features/tools within the HF Patient Management portfolio.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac Resynchronization Therapy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
* Patient has or is intended to receive or be treated with an eligible CRT device
* Patient within 30 days of therapy received at the time of their initial PSR platform enrollment

Exclusion Criteria

* Patient who is, or is expected to be inaccessible for follow-up
* Patient is currently enrolled in or plans to enroll in any concurrent drug and/ or device study that may confound results
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham, Alabama, United States

Site Status

Anchorage, Alaska, United States

Site Status

Gilbert, Arizona, United States

Site Status

Jonesboro, Arkansas, United States

Site Status

Little Rock, Arkansas, United States

Site Status

Bakersfield, California, United States

Site Status

Chula Vista, California, United States

Site Status

Palm Springs, California, United States

Site Status

Rancho Mirage, California, United States

Site Status

Redwood City, California, United States

Site Status

Salinas, California, United States

Site Status

San Diego, California, United States

Site Status

Stanford, California, United States

Site Status

Torrance, California, United States

Site Status

Van Nuys, California, United States

Site Status

Denver, Colorado, United States

Site Status

Lakewood, Colorado, United States

Site Status

New Haven, Connecticut, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Bradenton, Florida, United States

Site Status

Clearwater, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Safety Harbor, Florida, United States

Site Status

Albany, Georgia, United States

Site Status

Marietta, Georgia, United States

Site Status

Evansville, Indiana, United States

Site Status

Indianapolis, Indiana, United States

Site Status

West Des Moines, Iowa, United States

Site Status

Kansas City, Kansas, United States

Site Status

Edgewood, Kentucky, United States

Site Status

Louisville, Kentucky, United States

Site Status

Baton Rouge, Louisiana, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

Clinton, Maryland, United States

Site Status

Salisbury, Maryland, United States

Site Status

Silver Spring, Maryland, United States

Site Status

Takoma Park, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Worcester, Massachusetts, United States

Site Status

Lansing, Michigan, United States

Site Status

Marquette, Michigan, United States

Site Status

Ypsilanti, Michigan, United States

Site Status

Minneapolis, Minnesota, United States

Site Status

Robbinsdale, Minnesota, United States

Site Status

Rochester, Minnesota, United States

Site Status

Saint Louis Park, Minnesota, United States

Site Status

Columbia, Missouri, United States

Site Status

Kansas City, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Las Vegas, Nevada, United States

Site Status

Morristown, New Jersey, United States

Site Status

Ocean Township, New Jersey, United States

Site Status

Albuquerque, New Mexico, United States

Site Status

Garden City, New York, United States

Site Status

Huntington, New York, United States

Site Status

Manhasset, New York, United States

Site Status

New York, New York, United States

Site Status

Poughkeepsie, New York, United States

Site Status

Utica, New York, United States

Site Status

Durham, North Carolina, United States

Site Status

Raleigh, North Carolina, United States

Site Status

Akron, Ohio, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Portland, Oregon, United States

Site Status

Allentown, Pennsylvania, United States

Site Status

Bethlehem, Pennsylvania, United States

Site Status

Danville, Pennsylvania, United States

Site Status

Erie, Pennsylvania, United States

Site Status

Lancaster, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Wilkes-Barre, Pennsylvania, United States

Site Status

Columbia, South Carolina, United States

Site Status

Germantown, Tennessee, United States

Site Status

Kingsport, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

Dallas, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Plano, Texas, United States

Site Status

The Woodlands, Texas, United States

Site Status

Burlington, Vermont, United States

Site Status

Spokane, Washington, United States

Site Status

Madison, Wisconsin, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Leuven, , Belgium

Site Status

Yvoir, , Belgium

Site Status

Calgary, , Canada

Site Status

Kingston, , Canada

Site Status

Montreal, , Canada

Site Status

Québec, , Canada

Site Status

Clermont-Ferrand, , France

Site Status

La Rochelle, , France

Site Status

Montpellier, , France

Site Status

Nantes, , France

Site Status

Pringy, , France

Site Status

Aachen, , Germany

Site Status

Cologne, , Germany

Site Status

Essen, , Germany

Site Status

Hanover, , Germany

Site Status

Homburg, , Germany

Site Status

Tübingen, , Germany

Site Status

Ulm, , Germany

Site Status

Milan, , Italy

Site Status

Reggio Emilia, , Italy

Site Status

Kuala Lumpur, , Malaysia

Site Status

Eindhoven, , Netherlands

Site Status

Maastricht, , Netherlands

Site Status

Nieuwegein, , Netherlands

Site Status

Rotterdam, , Netherlands

Site Status

Belgrade, , Serbia

Site Status

Seoul, , South Korea

Site Status

A Coruña, , Spain

Site Status

Palma de Mallorca, , Spain

Site Status

Skövde, , Sweden

Site Status

Birmingham, , United Kingdom

Site Status

Liverpool, , United Kingdom

Site Status

Manchester, , United Kingdom

Site Status

Middlesbrough, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada France Germany Italy Malaysia Netherlands Serbia South Korea Spain Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Personalized CRT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Image Supported Lead Placement in CRT
NCT05053568 ACTIVE_NOT_RECRUITING NA